Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab
This study is looking at two medicines, nipocalimab and efgartigimod, which are used to treat a condition called generalised myasthenia gravis (gMG). gMG causes muscle weakness and tiredness. The main goal is to compare how effective nipocalimab is against efgartigimod. Researchers want to see if one medicine is better at reducing certain immune system proteins (IgG antibodies) that cause the illness. They are also looking at what happens when people switch from taking efgartigimod to nipocalimab. This research is important to help doctors understand the best ways to treat gMG and manage changes in treatment, so patients can feel better and have a better quality of life.
At a glance
What is this study about?
This study is a type of research called a 'clinical trial'. Its main purpose is to compare how two different medicines, nipocalimab and efgartigimod, work for people who have generalised myasthenia gravis (gMG). gMG is a long-term condition that makes your muscles weak and tired, because your body's immune system mistakenly attacks healthy tissues.
The researchers want to see which of these medicines is better at lowering the levels of certain proteins in the blood, called IgG antibodies. These antibodies are known to cause the symptoms of gMG. By comparing how much these antibodies are reduced over a certain period, the study hopes to understand which treatment is more effective.
Another important part of this study is to look at what happens when someone switches from taking efgartigimod to nipocalimab. Sometimes, a treatment might not work as well over time, or a different medicine might be more suitable. This part of the study will help doctors understand how people respond when their treatment is changed, which is very useful for managing gMG in the real world.
Key takeaways
- This study compares two treatments for generalised myasthenia gravis: nipocalimab and efgartigimod.
- It aims to see which medicine is more effective at reducing disease-causing antibodies.
- Researchers are also looking at how people respond when they switch from one treatment to the other.
- Participation involves regular clinic visits, health checks, and taking study medicine.
- The study is for adults (18 years and older) diagnosed with gMG.
- You can stop participating at any time without affecting your normal medical care.
Who may be eligible?
To join this study, you need to be an adult, 18 years of age or older. There is no upper age limit, meaning older adults can also take part. Both men and women are welcome to participate.
The study is specifically for people who have been diagnosed with generalised myasthenia gravis. There will be other specific health requirements that the study doctors will check to make sure the study is safe and suitable for you.
It's important to talk to your doctor if you are interested, as they will confirm if you meet all the necessary criteria to join this research.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with generalised myasthenia gravis?
- Are you able to attend regular clinic appointments?
- Are you currently in a stable health condition (apart from gMG)?
What does participation involve?
If you decide to take part in this study, you would first have health checks to confirm you're suitable. You would then be given either nipocalimab or efgartigimod, depending on which group you are in. These medicines are usually given as an infusion (into a vein) or an injection. You would have regular visits to the clinic for medical check-ups, blood tests, and to assess your muscle strength and any symptoms. The doctors will monitor your health closely throughout the study. You will also have follow-up visits after your treatment period. The total time you would be involved in the study would be explained to you in detail by the study team.
Potential risks and benefits
Locations (4)
- —UnverifiedAustria
- —UnverifiedGermany
- —UnverifiedSpain
- —UnverifiedItaly
Common questions
What is generalised myasthenia gravis (gMG)?
gMG is a long-term medical condition where your immune system attacks your body, causing weakness and tiredness in your muscles, especially in your eyes, face, throat, and limbs.
What kind of medicines are nipocalimab and efgartigimod?
These are both types of medicines called 'biologics' that work by targeting specific parts of your immune system to reduce the level of harmful antibodies in your body.
Why are researchers comparing these two medicines?
They want to find out which medicine is more effective at treating gMG and reducing the symptoms. They also want to understand what happens when people switch from one treatment to another.
Will I know which medicine I'm getting?
This is an 'open-label' study, which means that both you and the study doctors will know which treatment you are receiving.
Do I have to pay to be in the study?
No, you do not have to pay to participate in the study. All study-related treatments and visits are provided at no cost to you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.